{"id":38544,"date":"2026-05-22T09:47:00","date_gmt":"2026-05-22T13:47:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38544"},"modified":"2026-04-27T22:14:52","modified_gmt":"2026-04-28T02:14:52","slug":"australias-drug-patent-clock-the-complete-guide-to-how-long-protection-actually-lasts","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/australias-drug-patent-clock-the-complete-guide-to-how-long-protection-actually-lasts\/","title":{"rendered":"Australia’s Drug Patent Clock: The Complete Guide to How Long Protection Actually Lasts"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The Number Everyone Gets Wrong<\/h2>\n\n\n\n

Twenty years. Ask any pharma executive or patent attorney how long a drug patent lasts in Australia and you will almost always hear ’20 years.’ The answer is technically correct and practically misleading in equal measure.<\/p>\n\n\n\n

The real number \u2014 the one that drives revenue forecasts, generic entry strategies, and billion-dollar litigation decisions \u2014 sits somewhere between 7 and 25 years depending on which drug you are talking about, which patents cover it, and what happened in the Australian Federal Court last December.<\/p>\n\n\n\n

Australia’s pharmaceutical patent system is not a single dial set to 20. It is a cascade of overlapping protections: the standard patent term, a potential five-year extension for pharmaceutical substances, a separate five-year data exclusivity period under the Therapeutic Goods Act, and a patent notification system that determines when generic manufacturers can even start the clock on launching a competing product. And now, following a Full Federal Court decision handed down in December 2025 that has sent shockwaves through the industry and is currently pending before the High Court of Australia, decades of established practice around which patents qualify for an extension have been thrown into genuine legal uncertainty.<\/p>\n\n\n\n

For brand-name pharmaceutical companies, generic manufacturers, biosimilar developers, investors, and healthcare policy analysts, the practical question is never really ‘how long does a patent last?’ The question is: ‘When will competition arrive?’ These are not the same question. The answer to the second one involves patent terms, data exclusivity, regulatory timing, litigation risk, and a patent notification scheme that the Trump administration publicly called inadequate as recently as 2025.<\/p>\n\n\n\n

This guide works through each layer of the system in detail \u2014 from the foundational 20-year term to the most recent judicial and regulatory developments reshaping the landscape in real time. It draws on actual cases, real litigation outcomes, and publicly available regulatory data, including the kind of multi-patent, multi-jurisdiction tracking that platforms like DrugPatentWatch have made into a specialist intelligence discipline. Reading it from start to finish will give you a more complete picture of Australian pharmaceutical patent duration than most practising lawyers can recite from memory.<\/p>\n\n\n\n

\n\n\n\n

Part One: The Foundation \u2014 The Standard 20-Year Patent Term<\/strong><\/h2>\n\n\n\n

What the Patents Act 1990 Actually Says<\/strong><\/h3>\n\n\n\n

The starting point is Section 67 of the Patents Act 1990<\/em> (Cth), which sets the term of a standard patent at 20 years from the filing date of the patent application. Not from the date of grant. Not from the date of regulatory approval. Not from the date a drug reaches pharmacy shelves. From the date of filing the application.<\/p>\n\n\n\n

This distinction is foundational to understanding the entire discussion that follows, because it is the gap between filing date and commercial launch that defines the effective patent life of any pharmaceutical product \u2014 and that gap is where billions of dollars of exclusivity time get consumed before a single tablet reaches a patient.<\/p>\n\n\n\n

Standard patents are the main vehicle for pharmaceutical IP protection in Australia. The country also had an innovation patent system, though this was closed to new applications after August 2021, following amendments under the Intellectual Property Laws Amendment (Raising the Bar) Act 2012<\/em>. Existing innovation patents remain valid for their full eight-year terms. The innovation patent system was primarily relevant to medical devices and incremental improvements rather than novel pharmaceutical compounds.<\/p>\n\n\n\n

Australia is a member of the Patent Cooperation Treaty (PCT), which means most major pharmaceutical companies do not file directly in Australia first. They file an international PCT application, and Australia becomes a designated state. For PCT applications entering the Australian national phase, the 20-year term runs from the international filing date \u2014 typically the priority date of the earliest filed application in the patent family.<\/p>\n\n\n\n

This arrangement creates an immediate compression effect. By the time a PCT application is filed for a new drug, the candidate compound has usually been identified and the clock has started ticking on what will eventually become an Australian patent claim. The average time from patent filing to first regulatory approval for a pharmaceutical product globally runs around 10 to 12 years. In Australia, where the Therapeutic Goods Administration (TGA) requires its own evaluation process \u2014 even where it relies on comparable overseas regulators such as the US FDA or the European Medicines Agency \u2014 the timeline is broadly similar.<\/p>\n\n\n\n

A drug patented in 2010, when it was perhaps entering Phase I clinical trials, that receives TGA registration in 2022, starts earning commercial revenue with roughly eight years of nominal patent life remaining. Without any extension mechanism, the actual effective commercial exclusivity would be those eight years. The 20-year term, measured from filing, understates how much time has been consumed before the patent becomes commercially relevant.<\/p>\n\n\n\n

The Filing Date vs. the Grant Date: Why the Gap Matters<\/strong><\/h3>\n\n\n\n

There is a lag between patent filing and patent grant in Australia that typically runs 18 months to three or more years for pharmaceutical applications, depending on their complexity. IP Australia, the government body that administers patents, examines applications and can raise objections that extend prosecution. During this prosecution period, the patent does not yet confer any enforceable rights, though a granted patent does provide retrospective rights from the publication date under Section 57 of the Act.<\/p>\n\n\n\n

The grant date is irrelevant to calculating the patent term. What matters is the filing date. A patent filed in January 2005 and granted in March 2009 still expires in January 2025. This mirrors most major patent jurisdictions, but it means that pharmaceutical companies tracking protection in Australia must anchor their calendar to filing dates, not grant dates.<\/p>\n\n\n\n

For analysts modelling generic entry timelines, this requires access to the original filing date, which may differ substantially from when a drug first became publicly known as a commercial product. Tools like DrugPatentWatch cross-reference Australian patent data from AusPat (IP Australia’s public database) with Therapeutic Goods Administration registration records to surface these underlying filing dates and construct realistic exclusivity windows \u2014 a task that is far more complex in practice than it first appears [18].<\/p>\n\n\n\n

Why the 20-Year Term Is Only the Beginning<\/strong><\/h3>\n\n\n\n

Patent protection for pharmaceuticals in Australia rarely consists of a single patent with a single expiry date. A commercially significant drug typically accumulates a cluster of patents over its development and commercial life, each with a different filing date and therefore a different expiry date.<\/p>\n\n\n\n

At minimum, a brand-name pharmaceutical company will seek patent protection in Australia for the active pharmaceutical ingredient (API) itself, the specific salt, polymorph, or crystalline form most suitable for the drug product, key manufacturing processes or synthetic routes, specific formulations combining the API with excipients or delivery systems, and methods of treatment for specific therapeutic indications.<\/p>\n\n\n\n

Each represents a separate patent application, a separate prosecution history, and a separate expiry date. The API patent typically has the earliest filing date and therefore expires first. Formulation and method-of-use patents, filed later in development, expire later. This layered architecture \u2014 sometimes called a ‘patent thicket’ \u2014 is how brand-name companies extend practical market exclusivity well beyond the expiry of any single patent.<\/p>\n\n\n\n

In Australia, as in other major markets, the commercial significance of this architecture depends heavily on which patents the regulator and the courts consider relevant to a generic challenge. Generic manufacturers must navigate the full thicket, not just clear the earliest-expiring patent. That navigation is the central commercial and legal problem that the rest of this article addresses.<\/p>\n\n\n\n

\n\n\n\n

Part Two: The Patent Term Extension Regime \u2014 Up to Five More Years<\/strong><\/h2>\n\n\n\n

The Policy Rationale: Compensating for Regulatory Delay<\/strong><\/h3>\n\n\n\n

Section 70 of the Patents Act 1990<\/em> creates the mechanism by which certain pharmaceutical patents can be extended beyond their standard 20-year term. The maximum extension is five years, making the theoretical maximum patent term 25 years from the filing date.<\/p>\n\n\n\n

The policy rationale is straightforward. A pharmaceutical company that patents a new drug candidate while it is still in pre-clinical testing will consume a significant portion of its 20-year term before it can sell a single unit. The TGA registration process \u2014 which requires evaluation of safety and efficacy data \u2014 takes years. During that time, the patent clock is running. Without an extension mechanism, pharmaceutical patentees would have systematically shorter effective commercial exclusivity than inventors in other fields, since most inventions can be commercialised immediately after development, without regulatory approval. The Patent Term Extension (PTE) regime compensates for that asymmetry. <blockquote>’The development of a new drug is a long process, and often requires early patenting of the active substance to secure intellectual property rights prior to industry partnering or publication… pharmaceutical companies rely heavily on patents to generate the substantial cash flows needed to finance the development of new drugs from the discovery stage, through the pre-clinical and clinical development phases, to eventual marketing.’ \u2014 James &amp; Wells IP, <em>The Full Federal Backflip: Patent Term Extension Rejected on Pharmaceutical Formulation<\/em>, December 2025 [6]<\/blockquote><\/p>\n\n\n\n

Australia’s PTE regime was introduced by the Intellectual Property Laws Amendment Act 1998<\/em>. Its structure broadly mirrors similar mechanisms in other developed economies \u2014 the US Hatch-Waxman Act’s patent term restoration provisions, the EU Supplementary Protection Certificate system, and Japan’s own PTE regime \u2014 though the specific eligibility criteria, calculation methods, and limits differ in important ways.<\/p>\n\n\n\n

The Eligibility Criteria Under Section 70<\/strong><\/h3>\n\n\n\n

To qualify for a patent term extension under Section 70 of the Patents Act, a patent must satisfy four cumulative requirements.<\/p>\n\n\n\n

First, one or more pharmaceutical substances ‘per se’ must be in substance disclosed in the complete specification of the patent and in substance fall within the scope of at least one of the claims. The alternative pathway, available under Section 70(2)(b), covers pharmaceutical substances when produced by a process involving recombinant DNA technology \u2014 covering biologic drugs manufactured through genetic engineering techniques [15].<\/p>\n\n\n\n

Second, goods containing or consisting of the pharmaceutical substance must be included in the Australian Register of Therapeutic Goods (ARTG) \u2014 the register maintained by the TGA for approved medicines.<\/p>\n\n\n\n

Third, the period beginning on the patent’s filing date and ending on the first regulatory approval date for the substance must be at least five years. This five-year minimum threshold acts as a filter: if a drug received TGA registration within five years of the patent filing date, no extension is available. The rationale is that in such cases, the regulatory delay was not substantial enough to warrant compensation.<\/p>\n\n\n\n

Fourth, the patent term must not have been previously extended. Each eligible patent can only receive one extension [18].<\/p>\n\n\n\n

The timing of the application is governed by Section 71(2). A PTE application must be made during the term of the patent and within six months after the latest of: the date of commencement of the first inclusion of relevant goods in the ARTG, or the date of patent grant (whichever is later). This six-month window is strict. Missing it means forfeiting the extension entirely.<\/p>\n\n\n\n

The Calculation Formula: Section 77<\/strong><\/h3>\n\n\n\n

Once a PTE is granted, Section 77 of the Act sets the formula for calculating how long it runs. The extension equals the period beginning on the patent’s filing date and ending on the first regulatory approval date, minus five years.<\/p>\n\n\n\n

In practice: Extension = (First ARTG Registration Date \u2212 Patent Filing Date) \u2212 5 years.<\/p>\n\n\n\n

The extension is capped at five years. If the formula yields a longer period \u2014 which happens if the gap between filing and ARTG registration exceeds 10 years \u2014 the extension is still limited to five years [14].<\/p>\n\n\n\n

A worked example clarifies how this operates. Take a patent filed on 1 January 2000. The corresponding drug receives ARTG registration on 1 January 2013 \u2014 13 years after filing. The Section 77 calculation gives 13 minus 5, which equals 8 years. Since 8 years exceeds the five-year cap, the extension is five years. The standard patent would expire on 1 January 2020, and the extended term would expire on 1 January 2025.<\/p>\n\n\n\n

If the same patent achieved ARTG registration on 1 January 2009, just nine years after filing, the Section 77 calculation gives 9 minus 5, which equals 4 years. The extension is four years, and the patent expires on 1 January 2024.<\/p>\n\n\n\n

If registration occurred on 1 January 2006, six years after filing, the extension would be only one year. If registration occurred within five years of filing, there is no extension at all.<\/p>\n\n\n\n

What ‘First Regulatory Approval Date’ Actually Means: The PD-1 Inhibitor Dispute<\/strong><\/h3>\n\n\n\n

The phrase ‘first regulatory approval date’ sounds straightforward. It has generated some of the most expensive litigation in Australian pharmaceutical patent history.<\/p>\n\n\n\n

The central issue is this: if a patent claims a broad class of pharmaceutical substances, and a competitor’s product \u2014 which falls within the scope of the claims \u2014 receives ARTG registration before the patentee’s own product, does that competitor’s earlier registration date become the ‘first regulatory approval date’ for PTE calculation purposes?<\/p>\n\n\n\n

This question went to the heart of the dispute over the Ono Pharmaceutical\/Bristol-Myers Squibb patent covering PD-1 inhibitors \u2014 the class of immuno-oncology drugs that includes both Opdivo (nivolumab, marketed by BMS) and Keytruda (pembrolizumab, marketed by Merck\/MSD). Keytruda was listed on the ARTG approximately nine months before Opdivo. The Australian Patent Office’s initial position was that this earlier Keytruda registration was the ‘first regulatory approval date’ for the purpose of both the six-month filing window under Section 71 and the extension calculation under Section 77. This would have disadvantaged Ono and BMS substantially, since they had missed the six-month window calculated from the Keytruda date [10].<\/p>\n\n\n\n

The litigation wound through the Federal Court system. At first instance, Justice Beach held that it was for the patentee to nominate which pharmaceutical substance in the patent to use as the basis for the PTE application, and that the patentee’s own product could be nominated, triggering a six-month window from that product’s ARTG registration [14]. The Full Federal Court ultimately confirmed the ‘earliest first’ approach in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd<\/em> [2022] FCAFC 40 [12]. Under that decision, when a patent discloses multiple pharmaceutical substances separately listed in the ARTG, the PTE term extension will always be calculated from the earliest regulatory approval date \u2014 even if the patentee nominates a later-approved substance as the basis for the application [9].<\/p>\n\n\n\n

The practical implication is significant: patentees cannot ‘cherry-pick’ a later ARTG registration date for their own product when a competitor’s product within the patent’s scope reached market earlier. This requires careful portfolio management and monitoring of competitor products that may fall within broad patent claims.<\/p>\n\n\n\n

The Formulation Patent Earthquake: Otsuka v Sun Pharma<\/strong><\/h3>\n\n\n\n

Everything described above about PTE eligibility operated under a 30-year framework of consistent practice: pharmaceutical formulation patents \u2014 patents claiming specific combinations of an active ingredient with excipients, or specific delivery mechanisms \u2014 could qualify for extensions under Section 70, provided the other criteria were met.<\/p>\n\n\n\n

That framework collapsed in December 2025.<\/p>\n\n\n\n

In Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd<\/em> [2025] FCAFC 161, the Full Federal Court ruled unanimously that formulation patents do not qualify for PTEs under the Patents Act [44]. Only patents claiming active pharmaceutical ingredients can satisfy the Section 70(2)(a) requirement that the patent disclose and claim a ‘pharmaceutical substance per se.’<\/p>\n\n\n\n

The facts of the case are instructive. Otsuka owns Australian patent no. 2004285448, covering controlled release formulations of aripiprazole \u2014 the active ingredient in ABILIFY MAINTENA, a long-acting injectable used for schizophrenia and bipolar I disorder. Aripiprazole itself was a well-known compound, patented by others, and had been on the Australian market for years in immediate-release formulations. Otsuka’s patent was for the new delivery formulation combining aripiprazole with various excipients for the controlled-release effect. The standard 20-year patent term expired in October 2024. In 2014, Otsuka had obtained a PTE based on the ARTG registration of ABILIFY MAINTENA, extending protection to July 2029 [1].<\/p>\n\n\n\n

Sun Pharma, planning a generic aripiprazole injection launch, commenced Federal Court proceedings in 2023 challenging the PTE’s validity on the grounds that the Otsuka patent claims \u2014 which all included excipients as well as aripiprazole \u2014 did not meet the Section 70(2)(a) requirement. The trial judge disagreed and found that formulation patents could be eligible for PTEs. Sun Pharma filed a Notice of Contention on appeal, rearguing the formulation issue. The Full Court sided with Sun Pharma: the ‘pharmaceutical substance’ referred to in Section 70 is the active pharmaceutical ingredient that produces the therapeutic effect, not the formulation [1].<\/p>\n\n\n\n

The Full Court’s reasoning anchored in the text and legislative history. The definition of ‘pharmaceutical substance’ in the Act refers to a substance ‘whose application involves a chemical interaction, or physico-chemical interaction, etc., between it and a human physiological system.’ The Court held that it is the API \u2014 not the excipients or the delivery system \u2014 that has this interaction. Excipients are inert carriers. The formulation as a whole is not a pharmaceutical substance [42].<\/p>\n\n\n\n

The Court also noted that its interpretation is consistent with the PTE regime’s underlying policy. The years-long regulatory approval process that justifies extending pharmaceutical patents applies primarily to new active substances, not to reformulations of already-approved APIs. New formulations of approved drugs face a lighter regulatory burden; they do not require the full clinical trial programme that a new chemical entity must complete. Extending PTE eligibility to formulations would grant additional exclusivity in cases where the regulatory delay justifying that exclusivity does not really exist to the same degree [6].<\/p>\n\n\n\n

The decision overturned years of established Australian Patent Office practice and at least three first-instance Federal Court decisions that had held formulation patents eligible for PTEs [42]. Its practical consequences are immediate. Any currently valid PTE granted in respect of a formulation patent is now potentially invalid and can be challenged \u2014 either through Federal Court proceedings or through administrative rectification proceedings at IP Australia.<\/p>\n\n\n\n

The High Court Appeal: Where Things Stand in April 2026<\/strong><\/h3>\n\n\n\n

Otsuka applied for special leave to appeal to the High Court of Australia. In March 2026, the High Court granted that leave [30]. The case will now be heard by Australia’s highest court, with the Institute of Patent and Trade Mark Attorneys (IPTA) and Medicines Australia both seeking to intervene as amici curiae \u2014 underscoring the systemic importance of the question to the entire pharmaceutical sector.<\/p>\n\n\n\n

Pearce IP, one of Australia’s leading pharmaceutical patent firms, assessed Otsuka’s prospects as slim but not negligible. Fewer than 10% of special leave applications are granted (as Otsuka’s was), and the High Court will focus on whether the Full Court’s statutory interpretation was correct as a matter of law [34].<\/p>\n\n\n\n

For generic and biosimilar manufacturers, the uncertainty cuts both ways. The High Court might restore the pre-Otsuka position, reinstating formulation PTEs. In the meantime, formulation-based PTEs are legally vulnerable, and generic companies are already evaluating which extended protection periods can be challenged or circumvented before the High Court issues its judgment. Pearce IP described the current situation as a ‘perfect storm’ for the industry [37].<\/p>\n\n\n\n

The drugs affected span a wide range of therapeutic categories. Any originator product whose only currently active patent is a formulation patent on an extended term is now exposed to potential early generic competition. Biosimilar sponsors are similarly recalculating their timelines.<\/p>\n\n\n\n

\n\n\n\n

Part Three: Data Exclusivity \u2014 The Parallel Protection System<\/strong><\/h2>\n\n\n\n

What Data Exclusivity Is and Is Not<\/strong><\/h3>\n\n\n\n

Patents protect the intellectual property in a new invention. Data exclusivity protects something different: the clinical and preclinical data package a pharmaceutical company submits to the TGA to prove a drug’s safety and efficacy.<\/p>\n\n\n\n

Generating that data \u2014 running the clinical trial programme required for TGA registration \u2014 costs hundreds of millions of dollars and takes years. When a generic manufacturer wants to register a bioequivalent product, it does not repeat those trials. Instead, it relies on the data already submitted by the originator, demonstrating that its product is bioequivalent to the approved reference drug. The generic approval pathway assumes access to the originator’s scientific conclusions without requiring the generic to replicate the underlying work.<\/p>\n\n\n\n

Data exclusivity prevents generic manufacturers from relying on an originator’s undisclosed data for a fixed period after the drug’s first approval. During that period, even if every patent covering the drug has expired, a generic cannot obtain registration through the simplified bioequivalence pathway, because it cannot use the originator’s data to support its application.<\/p>\n\n\n\n

In Australia, data exclusivity is governed by Section 25A of the Therapeutic Goods Act 1989<\/em> and runs for five years from the first TGA registration of the reference product. The five-year period covers new chemical entities registered on the ARTG after 1 January 1999, consistent with Australia’s obligations under the TRIPS Agreement [22].<\/p>\n\n\n\n

How Data Exclusivity Interacts with Patents<\/strong><\/h3>\n\n\n\n

The five-year data exclusivity period and the pharmaceutical patent term operate independently. They can overlap, run consecutively, or coincide exactly \u2014 depending on the product’s filing and approval history.<\/p>\n\n\n\n

For a drug patented in 2000 and registered by the TGA in 2008, data exclusivity runs from 2008 to 2013. The compound patent, assuming no extension, expires in 2020. A generic manufacturer cannot rely on the originator’s data package before 2013, but since the patent does not expire until 2020, data exclusivity is not the binding constraint \u2014 patent expiry is. In this scenario, data exclusivity is effectively irrelevant to generic entry timing.<\/p>\n\n\n\n

For a drug with a very short development timeline \u2014 patented in 2005 and registered by 2007 \u2014 the patent expires in 2025, but data exclusivity expired in 2012. Again, patent expiry is the binding constraint.<\/p>\n\n\n\n

Data exclusivity becomes the binding constraint only when the relevant patents expire before the five-year data exclusivity period ends. This is uncommon for new chemical entities with full patent portfolios but can occur for drugs with short development pipelines or for new indications of existing drugs that generate fresh data exclusivity without fresh patent protection.<\/p>\n\n\n\n

DrugPatentWatch tracks both patent expiry and data exclusivity for products across major markets, including Australia, precisely because generic entry timing depends on which of the two constraints runs later. An analysis that tracks only patent expiry and ignores data exclusivity can produce materially wrong predictions about when competition will arrive [18].<\/p>\n\n\n\n

Data Exclusivity and Biologics<\/strong><\/h3>\n\n\n\n

For biologic drugs \u2014 large-molecule medicines produced by living cells \u2014 the regulatory approval pathway is different, and data exclusivity works differently too. Biosimilars cannot be approved via simple bioequivalence testing; they require extensive characterisation and, in some cases, clinical bridging studies to demonstrate similarity to the reference biologic.<\/p>\n\n\n\n

Australia does not have a specific data exclusivity regime for biologics equivalent to the 12-year exclusivity provided under US law for reference biological products under the Biologics Price Competition and Innovation Act. The TGA’s biosimilar registration framework uses the existing ARTG framework, and the five-year data exclusivity under Section 25A applies broadly to registered prescription medicines regardless of whether they are small molecules or biologics.<\/p>\n\n\n\n

In practice, biosimilar development timelines \u2014 and the complexity of demonstrating biosimilarity \u2014 mean that biologics face longer periods of effective market exclusivity even without special data exclusivity provisions. The commercial dynamics of biosimilar entry in Australia have been shaped less by data exclusivity rules and more by the specifics of the underlying patent portfolios and, increasingly, by the question of which of those patents can actually be extended under the post-Otsuka interpretation of Section 70.<\/p>\n\n\n\n

\n\n\n\n

Part Four: Patent Linkage in Australia \u2014 The Notification System<\/strong><\/h2>\n\n\n\n

A System That Doesn’t Fully Work<\/strong><\/h3>\n\n\n\n

In the United States, the FDA Orange Book connects patent protection directly to regulatory approval: an approved drug’s patents are listed in the Orange Book, generic applicants must certify their position on each listed patent, and a certification challenging a patent’s validity or asserting non-infringement triggers a litigation process with an automatic 30-month stay on generic approval. The system has been criticised for enabling delay and praised for providing clarity, but it leaves little ambiguity about what patents cover what drugs.<\/p>\n\n\n\n

Australia has nothing equivalent. The TGA maintains the ARTG, which records approved therapeutic goods. IP Australia maintains AusPat, which records patent filings and their status. The two databases do not communicate. There is no mechanism by which a company registering a drug in Australia is required to identify which patents cover it, and there is no public register of patent-drug linkages analogous to the US Orange Book [25].<\/p>\n\n\n\n

The patent notification system that does exist in Australia was introduced to satisfy Article 17.10(4) of the Australia-United States Free Trade Agreement<\/em> (AUSFTA), which entered into force in 2005 and required Australia to provide a system by which patent holders are notified when a generic manufacturer submits a product for marketing approval during the term of an existing patent. The system was implemented through Section 26B of the Therapeutic Goods Act 1989<\/em> [26].<\/p>\n\n\n\n

Under Section 26B, a generic manufacturer applying for TGA registration of a product must provide a certificate to the TGA. The certificate must state one of two things: either that the generic sponsor believes on reasonable grounds that marketing the product would not infringe a valid claim of a relevant patent, or that the sponsor has provided the patent owner with notice of its application.<\/p>\n\n\n\n

If the sponsor chooses the first option \u2014 certifying non-infringement without notifying the patentee \u2014 the patent holder may not learn about the pending generic application until after TGA approval is granted or even after the generic launches commercially. In such a scenario, the patent holder’s only option is to seek an interlocutory injunction from the Federal Court to prevent or stop the infringing launch, which is a costly and uncertain process [27].<\/p>\n\n\n\n

The Section 26B Loophole and Failed Reform<\/strong><\/h3>\n\n\n\n

The non-infringement certificate pathway creates what Griffith Hack IP attorneys described in early 2025 as a significant practical gap in Australia’s compliance with its AUSFTA obligations [25]. Patentees are effectively blind to potential generic challenges until the last moment, depriving them of the ability to assess infringement risk and commence proceedings before the generic product reaches pharmacies.<\/p>\n\n\n\n

Between 2019 and 2023, the TGA ran multiple consultation rounds on reforming the notification regime to require earlier disclosure of generic applications to patentees. The consultations attracted extensive submissions from both originator companies (who supported earlier notification) and generic manufacturers (who opposed it). In December 2023, the TGA updated its website to confirm that the proposed patent notification scheme ‘was not progressed’ \u2014 effectively killing the reform initiative, at least for now [25].<\/p>\n\n\n\n

The consequence is that Australia’s patent linkage system remains significantly weaker than the US system it was ostensibly designed to parallel. The Trump administration’s 2025 National Trade Estimate Report on Foreign Trade Barriers identified this as a concern, noting that ‘US and Australian pharmaceutical companies have expressed concerns about delays’ in the patent notification process [28]. There is ongoing pressure from US trade negotiators for Australia to adopt a more Orange Book-like system, though the Australian government and public health advocates have pushed back strongly, pointing out that strengthening patent linkage would delay generic entry and increase PBS costs.<\/p>\n\n\n\n

The Current System: How Generic Manufacturers Navigate It<\/strong><\/h3>\n\n\n\n

Under the current Section 26B framework, a generic manufacturer has two practical choices. It can take the ‘silent’ route: certify non-infringement without notifying the patentee, obtain TGA registration, and launch commercially, accepting the litigation risk of an infringement action and the possibility of an interlocutory injunction. Or it can take the ‘notification’ route: give the patentee notice of its application before TGA approval, triggering the patentee’s ability to commence infringement proceedings in the Federal Court.<\/p>\n\n\n\n

If the generic manufacturer gives notice and the patentee commences infringement proceedings in good faith, the patentee can seek an interlocutory injunction from the Federal Court to restrain the generic from launching while the patent dispute is resolved. However, the Australian system does not have a US-style automatic 30-month stay on generic approval triggered by patent litigation [23]. The 30-month duration sometimes referenced in Australian pharmaceutical policy discussions refers to the practical duration of litigation delays, not to an administrative mechanism comparable to the Hatch-Waxman stay.<\/p>\n\n\n\n

When the first generic lists on the Pharmaceutical Benefits Scheme, it triggers an automatic 25% price reduction applied to all versions of the drug on the PBS, including the brand-name version [28]. This mechanic makes the question of when, precisely, generic PBS listing occurs critically important to originator commercial strategy \u2014 and it gives generic manufacturers a strong incentive to list on the PBS immediately upon TGA approval.<\/p>\n\n\n\n

Medicines Australia’s White Paper on Patent Notification<\/strong><\/h3>\n\n\n\n

In March 2023, Medicines Australia \u2014 the peak body for research-based pharmaceutical companies in Australia \u2014 published a detailed white paper making the case for a formal patent notification scheme [24]. The paper argued that early notification would afford patentees time to consider infringement risks and negotiate with generic or biosimilar applicants to resolve or narrow disputes before litigation became necessary.<\/p>\n\n\n\n

The white paper noted that under the current system, generic sponsors can prepare for launch and potential litigation on their own timeline while patentees remain unaware of impending competition. In cases of private market launch \u2014 where a generic launches without PBS listing \u2014 the patentee may receive no advance warning at all. The paper argued this asymmetry was inconsistent with Australia’s AUSFTA obligations and created perverse incentives for litigation over negotiation [24].<\/p>\n\n\n\n

The TGA’s December 2023 decision not to progress the notification scheme left these concerns unresolved. The failed reform effort is now part of the ongoing US trade pressure on Australia, with the Trump administration’s 2025 trade report explicitly referencing it as a barrier to fair market access for US pharmaceutical companies.<\/p>\n\n\n\n

\n\n\n\n

Part Five: Effective Patent Life \u2014 The Number That Actually Matters<\/strong><\/h2>\n\n\n\n

The Gap Between Nominal and Effective Protection<\/strong><\/h3>\n\n\n\n

‘Effective patent life’ means the period during which a patent confers commercially meaningful exclusivity \u2014 that is, the time after the drug receives regulatory approval during which the patent prevents competitors from marketing equivalent products. It is the metric pharmaceutical companies and their investors actually care about, and it routinely diverges from the nominal patent term.<\/p>\n\n\n\n

For a new chemical entity in Australia, the typical pathway runs roughly as follows. A compound is identified and a patent application is filed during pre-clinical development. The patent has a 20-year term from that filing date. Clinical trials run for seven to ten years. TGA evaluation adds another one to two years. Regulatory approval arrives somewhere between eight and twelve years after patent filing. What remains of the patent term at that point is the nominal effective life before the basic compound patent expires.<\/p>\n\n\n\n

With a maximum five-year PTE added, effective patent life for a qualifying new chemical entity can stretch to perhaps 13 to 17 years. That is the range most pharmaceutical companies use for modelling return on R&D investment. Some drugs get more. Some drugs get less. The variation matters enormously for decisions about which candidates to develop and how to price approved drugs.<\/p>\n\n\n\n

A 2020 analysis published in the Journal of the American Medical Association<\/em> found that the mean capitalized investment to bring a new medicine to market between 2009 and 2018 was approximately USD 985 million, with mean total investment (including cost of capital) reaching USD 1.3 billion [7]. At those investment levels, every additional year of effective exclusivity is worth a very large amount of money, particularly for high-revenue products. The financial stakes explain why companies invest heavily in patent strategy and in litigation to protect or challenge PTEs.<\/p>\n\n\n\n

The Productivity Commission Critique<\/strong><\/h3>\n\n\n\n

Australia’s PTE regime has not gone unquestioned domestically. The Productivity Commission, in its 2016 Intellectual Property Arrangements Report, assessed the cost of patent term extensions to the PBS and broader government. The Commission estimated that the extension of term provisions cost the Australian Government approximately $240 million in the 2012-13 financial year in PBS-related expenditure alone \u2014 a figure that, in the longer term and including non-PBS revenue effects, was closer to $480 million annually [3].<\/p>\n\n\n\n

The Commission received evidence recommending that the effective patent life be reduced from approximately 15 years to 10 years, which the proponents estimated would save the PBS approximately $200 million per year based on pricing arrangements then in place [3]. These recommendations were not adopted. The PTE regime remained intact, though the policy debate around it \u2014 how much exclusivity is enough to incentivise innovation without excessively burdening public drug budgets \u2014 has never fully resolved.<\/p>\n\n\n\n

The December 2025 Otsuka decision effectively handed generic manufacturers a substantial policy win on this question without requiring legislative change. By restricting PTE eligibility to active pharmaceutical ingredients and excluding formulations, the Full Court narrowed the range of patents that can benefit from extended terms, and in doing so, accelerated the expiry of effective protection for a wide range of products whose exclusivity rested on formulation PTEs.<\/p>\n\n\n\n

Secondary Patents and the ‘Real’ Effective Patent Life<\/strong><\/h3>\n\n\n\n

For many commercial pharmaceutical products, the compound patent is not the last line of defence. By the time the compound patent expires, a company may have obtained secondary patents \u2014 on formulations, delivery devices, combination products, or specific methods of treatment \u2014 that continue to provide some protection.<\/p>\n\n\n\n

This layering of secondary patents is sometimes described pejoratively as ‘evergreening,’ a term that entered pharmaceutical policy discourse as a description of tactics that extend effective market exclusivity beyond what was originally intended by the patent system. Research on US regulatory approval data found that 84.6% of new branded formulations were approved before the first generic entered the market, suggesting systematic timing of reformulations to shift prescribers and patients to the new version before generic substitution of the original drug becomes available [6].<\/p>\n\n\n\n

The post-Otsuka world materially changes the calculus for this kind of lifecycle management in Australia. If formulation patents can no longer receive PTEs, the additional protection they provide is limited to their standard 20-year term from filing \u2014 without the bonus five years. For formulation patents filed well after the compound patent (typically the case, since reformulations are developed later in the lifecycle), the formulation patent may expire only modestly after the compound patent and provide a narrower window of lifecycle extension than was previously assumed.<\/p>\n\n\n\n

\n\n\n\n

Part Six: Real Cases, Real Timelines<\/strong><\/h2>\n\n\n\n

ABILIFY MAINTENA: The Aripiprazole Litigation<\/strong><\/h3>\n\n\n\n

The Otsuka\/Sun Pharma aripiprazole dispute has become the most consequential pharmaceutical patent case in Australia in recent memory. Its facts are a clean illustration of how the PTE system can create years of additional exclusivity \u2014 and how that additional exclusivity can be challenged.<\/p>\n\n\n\n

Otsuka’s aripiprazole formulation patent was filed in 2004. The standard 20-year term expired in October 2024. Otsuka obtained a PTE in 2014, extending protection to July 2029 \u2014 an additional four years and nine months of exclusivity based on the time between the patent’s effective date and the ARTG registration of ABILIFY MAINTENA [1].<\/p>\n\n\n\n

Sun Pharma’s generic was planned for April 2025. Without a successful PTE challenge, Sun Pharma would have been locked out of the Australian aripiprazole injection market until July 2029. The PTE was the commercial barrier, not any compound patent on aripiprazole itself (aripiprazole’s own patent had long since expired). The litigation was, at its core, about whether Otsuka could hold that market position for nearly five additional years on the strength of a formulation patent that had been validly extended \u2014 under then-prevailing law.<\/p>\n\n\n\n

The Full Court’s ruling in December 2025 invalidated the PTE. Sun Pharma’s path to market was cleared. The High Court has now agreed to hear Otsuka’s appeal, meaning the position could be reversed \u2014 but in the meantime, the extended protection is gone. This case demonstrates the magnitude of what is at stake in PTE litigation: not months, but years of market exclusivity, and the revenue that goes with it.<\/p>\n\n\n\n

Opdivo and Keytruda: When a Competitor’s Drug Starts Your Clock<\/strong><\/h3>\n\n\n\n

The dispute between Ono Pharmaceutical\/Bristol-Myers Squibb and the Australian Patent Office over PTE timing for their PD-1 inhibitor patent illustrates how the ‘first regulatory approval date’ calculation can produce counterintuitive results.<\/p>\n\n\n\n

Ono and BMS owned a patent covering monoclonal antibodies blocking the PD-1 immune checkpoint \u2014 a broad claim covering an entire class of cancer immunotherapy. Both Keytruda (pembrolizumab, MSD) and Opdivo (nivolumab, BMS) fell within the scope of this patent. Keytruda received ARTG registration approximately nine months before Opdivo.<\/p>\n\n\n\n

The Australian Patent Office’s initial view was that Keytruda’s earlier registration date triggered both the six-month filing window for a PTE application and the Section 77 calculation period [10]. This created a scenario where Ono and BMS \u2014 who had not sponsored Keytruda \u2014 were governed in their PTE application by a registration date they did not control and had no commercial relationship with.<\/p>\n\n\n\n

The Federal Court litigation explored the tension between a literal reading of the statute and a purposive one. Justice Beach’s first-instance ruling favoured a more patentee-friendly approach [14], though the Full Federal Court’s subsequent ruling in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd<\/em> confirmed the ‘earliest first’ approach \u2014 the PTE term is always calculated from the earliest ARTG registration of any pharmaceutical substance disclosed and claimed in the patent, regardless of who sponsored it [12].<\/p>\n\n\n\n

For patent portfolios covering broad drug classes where multiple competitors may develop products within the claims, this rule means that PTE calculations must account for competitor activity in the ARTG, not just the patentee’s own regulatory timeline.<\/p>\n\n\n\n

Linagliptin, Vortioxetine, and the Coming Expiry Wave<\/strong><\/h3>\n\n\n\n

Australia faces a wave of major patent expiries over the next few years. DrugPatentWatch’s tracking of Australian generic entry opportunity dates identifies multiple significant products approaching the end of their protection periods [19].<\/p>\n\n\n\n

Linagliptin \u2014 sold as Tradjenta by Boehringer Ingelheim for type 2 diabetes \u2014 has an estimated generic entry opportunity date of April 2027 in Australia, controlled by Australian Patent 2,007,247,193. Multiple tentatively approved generics are already positioned to enter the Australian market once that date arrives [19].<\/p>\n\n\n\n

Vortioxetine hydrobromide \u2014 sold as Brintellix for major depressive disorder \u2014 has an estimated generic entry date of June 2026, governed by Australian Patent 2,007,260,355 [19].<\/p>\n\n\n\n

Each of these approaching expiry dates represents a commercial inflection point: the originator faces revenue compression, the PBS gains pricing relief as generic entry triggers the 25% mandatory price reduction, and generic manufacturers compete to be first to market.<\/p>\n\n\n\n

The Otsuka decision adds a further dimension to every one of these calculations. For any product where the ‘controlling’ patent is a formulation patent on an extended term rather than a compound patent, the protection period is now subject to challenge. Generic manufacturers are actively auditing originator patent portfolios to identify which formulation-based PTEs are now vulnerable to rectification or litigation.<\/p>\n\n\n\n

The AstraZeneca Dapagliflozin Case: Injunctions in the New Climate<\/strong><\/h3>\n\n\n\n

AstraZeneca AB v Pharmacor Pty Ltd<\/em> [2026] FCA 88, decided in February 2026, shows the interlocutory injunction dynamic playing out in the new litigation climate. AstraZeneca sought to restrain Pharmacor from launching a generic dapagliflozin product (the active ingredient in Forxiga, used for type 2 diabetes and heart failure) while patent proceedings were resolved [36].<\/p>\n\n\n\n

The Federal Court granted the injunction in AstraZeneca’s favour \u2014 one of a small number of successful pharmaceutical injunction applications in recent years. The contrast with the Regeneron\/Sandoz aflibercept case decided just months earlier (where the injunction was refused) illustrates that the Federal Court’s approach is fact-specific, weighing the strength of the infringement and invalidity arguments, the commercial impact of the PBS price reduction mechanism, and the balance of convenience between the parties [36].<\/p>\n\n\n\n

For practising pharmaceutical lawyers, the lesson from these cases is that interlocutory injunctions are available in Australia, but obtaining one requires a strong prima facie infringement case that is not significantly undermined by a correspondingly strong invalidity argument. In cases involving formulation PTEs, the Otsuka ruling makes it much harder for originators to sustain a strong prima facie case for the extension’s validity \u2014 which in turn makes the injunction harder to obtain.<\/p>\n\n\n\n

\n\n\n\n

Part Seven: The Biosimilar Landscape<\/strong><\/h2>\n\n\n\n

How Biologics Age Differently<\/strong><\/h3>\n\n\n\n

The lifecycle management challenges for biologic drugs are structurally different from those for small molecules. Biologic drugs cannot be replicated with simple chemistry. Their manufacture is inherently more variable, tied to specific cell lines and production processes. This complexity makes biologic patent portfolios both harder to construct and harder to challenge.<\/p>\n\n\n\n

For originators of biologic drugs, the key patents typically cover the antibody or protein itself (at the compound level), the manufacturing process used to produce it, specific formulations, and methods of treatment or dosing regimens. In Australia, Section 70(2)(b) of the Patents Act specifically allows PTEs for pharmaceutical substances produced by recombinant DNA technology, confirming that biologic APIs are eligible for extensions.<\/p>\n\n\n\n

The Otsuka ruling does not obviously change the PTE calculus for pure API or recombinant-technology patents covering biologics. What it does change is the position of any formulation patents that a biologic manufacturer may have obtained for specific formulation or delivery innovations. Those formulation patents, if on extended terms, are now subject to the same vulnerability as small-molecule formulation PTEs.<\/p>\n\n\n\n

Biosimilar Entry Dynamics on the PBS<\/strong><\/h3>\n\n\n\n

One insight that emerges clearly from markets that have experienced biosimilar competition is that biologics do not follow the same price collapse dynamics as small-molecule generic entry. DrugPatentWatch’s patent cliff analysis notes that in the US, biosimilars captured only approximately 20-30% of volume within two years of biologic loss of exclusivity, compared to the 90% market share capture seen for small molecules within 18 months [20].<\/p>\n\n\n\n

Australia’s PBS structure creates both accelerators and decelerators for biosimilar uptake. The mandatory 25% price reduction triggered by the first biosimilar listing applies to all biosimilars and the reference biologic, compressing prices across the market. Clinician inertia \u2014 the tendency of prescribers to continue with established therapies rather than switching established patients to biosimilars \u2014 means volume shift is slower than price shift. The TGA has worked to build confidence in biosimilar products through its approval framework, which requires demonstration of biosimilarity to the reference product.<\/p>\n\n\n\n

This regulatory approval framework is distinct from any patent question \u2014 a biosimilar can receive TGA approval and PBS listing regardless of outstanding patent disputes, though it may face injunction proceedings from the originator if patent infringement issues are live. Biosimilar sponsors are therefore well-served by auditing originator patent portfolios carefully before launch \u2014 not to avoid PBS listing, but to anticipate the likelihood and strength of any injunction application they may face.<\/p>\n\n\n\n

\n\n\n\n

Part Eight: Monitoring and Intelligence \u2014 Knowing What You Don’t Know<\/strong><\/h2>\n\n\n\n

The Data Challenge: AusPat, ARTG, and the Gap Between Them<\/strong><\/h3>\n\n\n\n

Tracking pharmaceutical patent expiry in Australia requires reconciling two separate official databases that do not communicate with each other.<\/p>\n\n\n\n

AusPat, maintained by IP Australia, is the primary database for patent filing and status information. It records filing dates, grant dates, renewal status, any PTE applications and their outcomes, and legal proceedings affecting patents. It is the authoritative source for what patents exist and whether they are in force.<\/p>\n\n\n\n

The ARTG, maintained by the TGA, records approved therapeutic goods \u2014 the drugs, biologics, and medical devices that have received marketing authorisation in Australia. It identifies sponsors, active ingredients, formulations, and regulatory approval dates. It does not directly link products to patents.<\/p>\n\n\n\n

Matching a specific ARTG-registered drug to the patents that cover it requires cross-referencing the two databases using the active ingredient, the product name, the sponsor’s corporate identity, and often patent prosecution documents that are not straightforwardly indexed. This is a resource-intensive exercise that most teams cannot replicate at scale without specialist tools.<\/p>\n\n\n\n

This is the gap that platforms like DrugPatentWatch address directly. By aggregating patent filing data, regulatory approval records, and litigation history across jurisdictions, DrugPatentWatch allows pharmaceutical companies, generic manufacturers, and investment analysts to construct complete exclusivity timelines for specific products without manually reconciling multiple fragmented databases [18]. In the Australian context \u2014 where there is no Orange Book equivalent and where AusPat and the ARTG must be reconciled separately \u2014 this kind of integrated intelligence is particularly valuable.<\/p>\n\n\n\n

For generic manufacturers planning an Australian market entry, the analysis must cover at minimum: which compound patents remain in force on the active ingredient, whether any PTE has been granted and what its status is, whether any formulation or method-of-use patents are in force, when data exclusivity expires, and what the current litigation environment looks like. The Otsuka decision adds a further layer: whether any existing PTEs are of the formulation type and therefore now potentially subject to challenge.<\/p>\n\n\n\n

The ‘Patent Cliff’ in Australian Terms<\/strong><\/h3>\n\n\n\n

The term ‘patent cliff’ \u2014 the concentrated loss of market exclusivity across multiple major products within a defined period \u2014 applies in Australia as in other markets, though the specific timeline and products differ from the US or EU experience.<\/p>\n\n\n\n

DrugPatentWatch identifies 37 drugs facing patent expiry and generic entry in Australia in the 2026-2027 window [19]. This list spans therapeutic areas including diabetes management, cardiovascular disease, psychiatry, and neurology. The PBS pricing dynamics amplify the cliff effect: each new generic listing triggers the mandatory 25% price reduction for all versions of that product on the PBS, compressing originator revenue not just through volume loss but through price cuts on retained brand sales.<\/p>\n\n\n\n

For healthcare budget planners at the Australian Government Department of Health, approaching patent cliffs represent a source of PBS expenditure relief \u2014 as generic competition drives down the per-unit cost of medicines. The Productivity Commission’s analysis of PBS savings showed that generic competition could lead to price falls of 35% or more under PBS pricing arrangements [3]. For originator companies, those same cliff moments require careful management of brand loyalty, clinical differentiation, and in some cases, commercial exits from specific product lines.<\/p>\n\n\n\n

\n\n\n\n

Part Nine: The Geopolitical Dimension \u2014 US Trade Pressure and the PBS<\/strong><\/h2>\n\n\n\n

AUSFTA’s Long Shadow<\/strong><\/h3>\n\n\n\n

The Australia-United States Free Trade Agreement, which entered into force in 2005, reshaped Australia’s pharmaceutical patent landscape in ways that continue to generate controversy. Article 17.10 of the AUSFTA’s intellectual property chapter introduced obligations that pushed Australia toward a more US-aligned pharmaceutical patent protection framework \u2014 specifically around patent linkage, regulatory data protection, and the transparency of marketing approval processes.<\/p>\n\n\n\n

The Section 26B notification system is a direct product of AUSFTA implementation. So are the compensation provisions that can require patent holders who commence unsuccessful infringement litigation against generic manufacturers to pay compensation for the delay caused to generic entry [23]. These compensation provisions were included as a counterbalance \u2014 recognising that a system where patent holders are notified of generic applications creates the risk of strategic litigation to delay competition.<\/p>\n\n\n\n

The tension in the current system is structural. AUSFTA Article 17.10(4) requires that patent holders be informed of generic marketing approval applications. The Section 26B certificate mechanism allows generic sponsors to avoid giving that notice if they certify non-infringement directly to the TGA. The US pharmaceutical industry has consistently argued that Australia’s implementation does not fully meet its AUSFTA obligations [25].<\/p>\n\n\n\n

The Trump administration’s 2025 trade report explicitly flagged Australia’s pharmaceutical patent notification system as a barrier to trade. This creates pressure in the context of any renegotiation or update of US-Australia trade frameworks to strengthen patent linkage in Australia \u2014 which in practice means making it harder and slower for generic medicines to enter the Australian market [28].<\/p>\n\n\n\n

Australian public health advocates have pushed back firmly. They point out that the 25% PBS price reduction triggered by the first generic listing compounds over time, and that keeping generics off the PBS for longer directly increases government drug expenditure. An article in The Conversation in May 2025, written by health economists, estimated that changing Australia’s system to be more like the US 30-month automatic stay would delay generics, keep PBS costs higher, and represent a direct transfer of value from the Australian public health budget to US pharmaceutical companies [28].<\/p>\n\n\n\n

The PBS as a Pricing Anchor<\/strong><\/h3>\n\n\n\n

The Pharmaceutical Benefits Scheme’s reference pricing mechanisms make Australia’s patent expiry dynamics distinctive in the global context. The PBS is not a passive payer \u2014 it actively negotiates and structures drug prices, and the rules about when and how prices change upon generic entry are precisely defined.<\/p>\n\n\n\n

The 25% mandatory price reduction on PBS listing of the first generic has already been described. Beyond that initial reduction, the PBS pricing framework includes further scheduled reductions as additional generics enter the market. Over time, substantial generic competition can drive PBS prices to levels far below the original brand price \u2014 and sometimes below the PBS co-payment threshold, which eliminates the government’s contribution for those patients entirely.<\/p>\n\n\n\n

For companies modelling Australian revenue projections, the PBS price reduction cascade must be factored in alongside the volume erosion from generic substitution. A drug that retains high market share but faces mandatory price reductions after generic PBS listing will see revenue fall regardless of its commercial brand loyalty. This is a distinctly Australian characteristic of the patent cliff calculation.<\/p>\n\n\n\n

For the argument about patent term length, the PBS context matters. Australia’s government has a direct fiscal interest in earlier generic entry \u2014 it translates to lower PBS costs. This creates a natural alignment between government procurement interests and the outcomes favoured by generic manufacturers, and it shapes how Australian courts and regulators approach the policy tradeoffs in pharmaceutical patent disputes.<\/p>\n\n\n\n

\n\n\n\n

Part Ten: The Road Ahead \u2014 What Changes After Otsuka<\/strong><\/h2>\n\n\n\n

IP Australia’s Rectification Process<\/strong><\/h3>\n\n\n\n

Following the Full Court’s ruling in Otsuka, IP Australia \u2014 the body that administers the patent register \u2014 has the power to initiate proceedings to rectify the Australian Patent Register by revoking PTEs that were granted in respect of formulation patents [36]. This administrative rectification process does not require the originator company to take any action. The Commissioner of Patents can initiate it unilaterally.<\/p>\n\n\n\n

Competing pharmaceutical companies and generic manufacturers can also initiate court proceedings to revoke formulation-based PTEs, or they can launch their products at commercial risk \u2014 entering the market without waiting for the PTE to expire, on the basis that the PTE is now invalid under the Otsuka ruling [33].<\/p>\n\n\n\n

Patent attorneys at Bird & Bird, Allens, Dentons, Clayton Utz, and Pearce IP have all published urgent guidance to pharmaceutical clients advising them to audit their Australian patent portfolios and identify any PTEs that are now at risk. The key question for each PTE is: does the underlying patent claim an active pharmaceutical ingredient per se, or does it claim a formulation of an API? If the latter, the PTE is potentially invalid [33].<\/p>\n\n\n\n

For originators with formulation-based PTEs, the practical options are limited. They can await the High Court decision in Otsuka while hoping for a favourable reversal, or they can begin transition planning for earlier-than-anticipated generic competition. Companies that had modelled revenue through 2029 or 2030 on the basis of PTE protection may now be recasting those models with expiry dates falling two or more years earlier.<\/p>\n\n\n\n

The High Court’s Decision: What to Watch For<\/strong><\/h3>\n\n\n\n

The High Court will hear Otsuka’s appeal at some point in 2026 or 2027. The core question before the Court is whether the Full Federal Court correctly interpreted the definition of ‘pharmaceutical substance’ in Section 70(2) of the Patents Act.<\/p>\n\n\n\n

Otsuka’s central argument, as set out in its special leave application, is that the Full Court’s interpretation is inconsistent with the ordinary and natural meaning of the statutory words, that Parliament has had repeated opportunities to expressly exclude formulations from PTE eligibility and has not done so, and that the decision creates significant legal uncertainty for the pharmaceutical sector [34].<\/p>\n\n\n\n

The industry bodies IPTA and Medicines Australia have both filed to intervene, reflecting broad concern about the systemic implications of the Full Court’s ruling. Their submissions are expected to focus on the interpretation of the statutory definition and on the policy consequences of restricting PTE eligibility to APIs.<\/p>\n\n\n\n

The counterarguments, likely to be advanced by Sun Pharma and potentially supported by generic industry bodies, will focus on legislative intent: the PTE regime was designed to compensate for regulatory delay in bringing new chemical entities to market, and formulations of already-approved APIs do not require the same lengthy approval process that justifies the extension. Granting PTEs for formulations extends exclusivity in cases where the underlying justification does not fully apply.<\/p>\n\n\n\n

If the High Court overturns the Full Court, formulation PTEs are restored and the landscape reverts to the pre-December 2025 position. If the High Court affirms the Full Court, formulation PTEs are definitively gone, and IP Australia’s rectification process will work through the register to remove them.<\/p>\n\n\n\n

Either outcome has enormous financial implications. The aggregate revenue at stake across all formulation-patent PTEs in Australia \u2014 through avoided PBS expenditure alone \u2014 runs to hundreds of millions of dollars annually.<\/p>\n\n\n\n

Preliminary Injunctions: Another Shifting Front<\/strong><\/h3>\n\n\n\n

The Otsuka decision is not the only development reshaping the litigation landscape for pharmaceutical patents in Australia. Chambers & Partners’ Patent Litigation 2026 review for Australia identifies a parallel trend: courts are becoming more reluctant to grant interlocutory injunctions restraining generic or biosimilar launches in pharmaceutical patent disputes [36].<\/p>\n\n\n\n

The Federal Court in Regeneron Pharmaceuticals v Sandoz<\/em> [2025] FCA 1067 declined to grant an injunction restraining Sandoz’s launch of an aflibercept biosimilar, despite arguable infringement claims [36]. This reluctance reflects the Court’s assessment of the balance of convenience: once a generic launches on the PBS, triggers the 25% price reduction, and establishes a market position, the status quo is very difficult to restore through a later injunction or damages award.<\/p>\n\n\n\n

The Federal Court in Janssen Pharmaceutica v Juno Pharmaceuticals<\/em> [2025] FCA 1538 did grant an interlocutory injunction where the prima facie infringement case was particularly strong and the invalidity case was weaker [36]. The contrast between these two 2025 decisions illustrates that injunctive relief remains available in appropriate cases, but the bar is higher than it once was, and the PBS price dynamics weigh heavily in the balance-of-convenience analysis.<\/p>\n\n\n\n

For originators considering whether to file for an injunction against a generic launch, this landscape means careful analysis of the strength of the infringement claim, the likely validity of the relevant patents (which now includes the Otsuka question for any formulation-based protection), and the likely PBS pricing impact of a generic PBS listing during the period of any injunction.<\/p>\n\n\n\n

\n\n\n\n

Part Eleven: Strategic Implications \u2014 A Practical Framework<\/strong><\/h2>\n\n\n\n

For Brand-Name Pharmaceutical Companies<\/strong><\/h3>\n\n\n\n

The first priority in the current environment is patent portfolio auditing, focused specifically on identifying which Australian patents covering commercial products have received PTEs and whether those PTEs are for compound patents or formulation patents.<\/p>\n\n\n\n

For compound patent PTEs, the analysis under Section 70 and Section 77 remains broadly intact. The eligibility requirements, the timing rules, the calculation formula, and the cap at five years all continue to apply as they did before the Otsuka decision. Compound patent PTEs are not at risk from that ruling.<\/p>\n\n\n\n

For formulation patent PTEs, the position is live risk. Each such PTE should be assessed against the following questions: does the patent claim the API itself, or does it claim a formulation that includes excipients alongside the API? If the patent claims a formulation, the PTE is potentially invalid under Otsuka, and the company should model its commercial exposure on the basis of no extended protection.<\/p>\n\n\n\n

The second priority is monitoring competitor activity in the ARTG. Under the Merck Sharp & Dohme confirmation of the ‘earliest first’ rule, if a competitor’s product that falls within the scope of a patent receives ARTG registration before the patentee’s own product, that earlier date controls the PTE calculation and filing window. Patentees with broad claims must monitor the ARTG for competitor registrations that could affect their PTE timing.<\/p>\n\n\n\n

The third priority is engagement with the High Court Otsuka process. The outcome of that appeal will definitively resolve the formulation PTE question. Companies with material revenue exposure to formulation PTEs should be following the proceedings closely and scenario-planning for both outcomes.<\/p>\n\n\n\n

For Generic and Biosimilar Manufacturers<\/strong><\/h3>\n\n\n\n

The Otsuka decision has created market entry opportunities that did not exist six months ago. Any product that was effectively blocked by a formulation-based PTE \u2014 where the compound patent had expired but the formulation PTE was running \u2014 is a potential early entry opportunity. The first step is identifying these products by auditing the ARTG and AusPat for formulation PTEs currently in their extended period.<\/p>\n\n\n\n

Once a target product is identified, the generic manufacturer can consider challenging the PTE through administrative rectification at IP Australia or through Federal Court proceedings, or launching at commercial risk without waiting for the challenge to resolve. Each approach carries different risk and cost profiles.<\/p>\n\n\n\n

Launching at risk during a formulation PTE extended period means the originator could still seek an interlocutory injunction. Under the current judicial climate, however \u2014 where courts are more reluctant to grant injunctions and the Otsuka ruling substantially undermines the originator’s patent position \u2014 the risk of a successful injunction is lower than it was before December 2025.<\/p>\n\n\n\n

The TGA approval and PBS listing process remains the same regardless of the patent dispute outcome. Generic manufacturers should pursue TGA registration in parallel with any PTE challenge, so that they can move to PBS listing promptly once the patent question is resolved or the decision to launch at risk is made.<\/p>\n\n\n\n

For Healthcare Policy Analysts and PBS Budget Planners<\/strong><\/h3>\n\n\n\n

The Otsuka decision is, in PBS budget terms, a positive development: it has effectively accelerated the expiry date of a category of pharmaceutical protection that had been costing the Australian government money through delayed generic entry.<\/p>\n\n\n\n

The Productivity Commission’s earlier analysis of PBS savings from generic entry remains a reference point, though the specific numbers require updating. As more formulation PTEs become vulnerable to challenge, more generic entries will occur earlier than previously modelled, generating more PBS price reductions sooner.<\/p>\n\n\n\n

The ongoing US trade pressure to strengthen Australia’s patent notification system cuts in the opposite direction. If Australia were to adopt a US-style automatic 30-month stay on generic approval \u2014 which the Trump administration’s 2025 trade report effectively advocated \u2014 that would offset some of the PBS savings created by the Otsuka ruling by delaying generic entry through administrative process rather than through the validity of any specific patent [28].<\/p>\n\n\n\n

\n\n\n\n

Part Twelve: How Long Do Drug Patents Last in Australia? The Definitive Answer<\/strong><\/h2>\n\n\n\n

The Framework, Assembled<\/strong><\/h3>\n\n\n\n

After working through each layer of the system, the answer to ‘how long do drug patents last in Australia?’ can be stated with reasonable precision.<\/p>\n\n\n\n

The standard term is 20 years from the patent filing date. This is the baseline set by Section 67 of the Patents Act 1990.<\/p>\n\n\n\n

For pharmaceutical substances meeting the eligibility criteria in Section 70, an additional extension of up to five years is available, making the maximum nominal term 25 years from filing. This extension requires that the patent claim a pharmaceutical substance per se or a substance produced by recombinant DNA technology, that the substance be registered on the ARTG, that at least five years elapsed between the filing date and first ARTG registration, and that no previous extension has been granted. Following the Otsuka Full Federal Court decision of December 2025 \u2014 and pending the High Court’s resolution of Otsuka’s appeal \u2014 formulation patents are not eligible for this extension [38].<\/p>\n\n\n\n

Data exclusivity under Section 25A of the Therapeutic Goods Act 1989 provides five years of protection for the clinical and preclinical data package submitted for ARTG registration. Generic manufacturers cannot rely on that data package for five years from first registration, which can delay generic market entry independently of any patent [22].<\/p>\n\n\n\n

The practical effective exclusivity period \u2014 the period during which a drug actually faces no competition \u2014 varies widely. For a typical new chemical entity in Australia, effective commercial exclusivity runs from 7 to 12 years from first registration without a PTE, or from 12 to 17 years from first registration with a PTE. These ranges are rough approximations and vary substantially based on specific filing timelines, regulatory approval speed, data exclusivity overlap, and the breadth and strength of the surrounding patent portfolio.<\/p>\n\n\n\n

Secondary patents \u2014 covering formulations, salts, polymorphs, combinations, and methods of use \u2014 can extend the period during which a brand-name product faces no direct competitive challenge, though each secondary patent must be individually assessed for enforceability and PTE eligibility under the current post-Otsuka framework.<\/p>\n\n\n\n

The Variables That Change the Calculation<\/strong><\/h3>\n\n\n\n

Three variables move the effective exclusivity needle most substantially for any specific drug in Australia.<\/p>\n\n\n\n

The gap between patent filing and TGA registration is the first. The larger this gap, the larger the potential PTE (up to the five-year cap). For drugs with long clinical development histories, effective patent life after registration is shorter, but the PTE may compensate. For drugs with short development timelines, the PTE may be small or unavailable.<\/p>\n\n\n\n

The type of patent at the end of the exclusivity chain is the second. A compound patent on an extended term provides a different protection profile from a formulation patent on an extended term. After Otsuka, the latter is much weaker.<\/p>\n\n\n\n

The litigation environment is the third. The timing of generic entry ultimately depends on whether any patent dispute gets resolved before or after the nominal expiry dates. An originator that can successfully defend a compound PTE through interlocutory injunction proceedings buys time \u2014 potentially years \u2014 beyond the nominal expiry date. A generic manufacturer that successfully challenges formulation PTEs early can enter before the nominal extended term expires.<\/p>\n\n\n\n

Data from DrugPatentWatch’s Australian product tracking incorporates all these variables \u2014 filing dates, ARTG registration dates, PTE applications, litigation histories, and PBS listing status \u2014 into integrated exclusivity timelines that reflect the actual legal and regulatory position of each drug, not just the face value of the 20-year nominal term [18].<\/p>\n\n\n\n

\n\n\n\n

Conclusion: The Clock Is Not What It Appears<\/h2>\n\n\n\n

Australia’s pharmaceutical patent system is a layered construct that produces effective drug protection periods ranging from under eight years to over twenty years, depending on the specific product and its regulatory and litigation history. The ’20-year patent term’ is the floor of the analysis, not the answer to it.<\/p>\n\n\n\n

The December 2025 Full Federal Court ruling in Otsuka v Sun Pharma<\/em> has changed the calculus for formulation-based patent term extensions in ways that are still working themselves out. The High Court’s decision \u2014 expected no earlier than late 2026 \u2014 will set the definitive framework. In the meantime, the Australian pharmaceutical patent landscape is genuinely uncertain in ways it has not been for nearly three decades.<\/p>\n\n\n\n

For any commercial actor with material exposure to Australian pharmaceutical patent timelines \u2014 whether as originator, generic manufacturer, biosimilar developer, investor, or public health payer \u2014 the appropriate response to that uncertainty is active portfolio monitoring, scenario planning for both High Court outcomes, and access to integrated patent and regulatory data that goes beyond face-value expiry dates.<\/p>\n\n\n\n

The 20-year clock is real. What runs alongside it, and what replaces it, is the story that actually determines when competition arrives.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

1. The standard patent term is 20 years from filing, not from approval.<\/strong> Because pharmaceutical development takes 8-12 years, effective commercial exclusivity from registration is typically 8-12 years before accounting for any extension.<\/p>\n\n\n\n

2. Patent Term Extensions of up to five years are available for qualifying pharmaceutical patents.<\/strong> The extension is calculated by subtracting five years from the gap between the patent filing date and first ARTG registration, capped at five years. After the December 2025 Otsuka Full Federal Court decision, only patents claiming active pharmaceutical ingredients currently qualify.<\/p>\n\n\n\n

3. Data exclusivity under Section 25A of the Therapeutic Goods Act provides a separate five-year protection period<\/strong> for the clinical data package submitted to the TGA, running from first product registration. It can independently delay generic entry even after patent expiry, though it is rarely the binding constraint for products with full patent portfolios.<\/p>\n\n\n\n

4. Australia’s patent linkage system is significantly weaker than the US Orange Book model.<\/strong> The Section 26B certificate mechanism allows generic manufacturers to avoid notifying patentees of pending applications by self-certifying non-infringement, and a proposed reform to strengthen notification was abandoned by the TGA in December 2023.<\/p>\n\n\n\n

5. The Otsuka v Sun Pharma decision \u2014 under High Court appeal as of March 2026 \u2014 has invalidated decades of practice allowing formulation patents to receive PTEs.<\/strong> Any currently extended formulation patent PTE is now potentially subject to administrative rectification or court challenge, accelerating generic entry for affected products.<\/p>\n\n\n\n

6. The PBS price dynamics compound patent expiry effects.<\/strong> The first generic PBS listing triggers an automatic 25% price reduction applied to all versions of the drug, including the brand-name product. Subsequent generic listings drive further price compression, creating a price cascade that operates independently of patent litigation outcomes.<\/p>\n\n\n\n

7. No single expiry date tells the full story.<\/strong> A complete picture of pharmaceutical exclusivity in Australia requires cross-referencing compound patent expiry dates, formulation patent expiry dates, PTE applications and their validity under current law, data exclusivity periods, and the regulatory and litigation status of pending generic applications.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: Can a pharmaceutical company receive both a Patent Term Extension and benefit from data exclusivity at the same time in Australia?<\/strong><\/p>\n\n\n\n

Yes. The PTE and data exclusivity operate under different legislative frameworks \u2014 the PTE under the Patents Act 1990 and data exclusivity under the Therapeutic Goods Act 1989 \u2014 and they run concurrently or consecutively depending on the specific product’s timeline. They address different rights: the PTE extends the patent grant’s enforceability, while data exclusivity prevents generic manufacturers from relying on the originator’s regulatory data package. A product with both a valid PTE and active data exclusivity benefits from both protections simultaneously, but data exclusivity is typically the less commercially significant constraint for products with full patent portfolios, since the five-year data exclusivity period usually expires well before the patent term.<\/p>\n\n\n\n

Q2: After the Otsuka Full Federal Court decision, are all existing formulation patent PTEs immediately invalid?<\/strong><\/p>\n\n\n\n

Not automatically. The Full Court’s ruling means that formulation patents are not eligible for PTEs under Section 70 of the Patents Act, but an existing PTE granted in respect of a formulation patent does not vanish from the register without a formal legal step. The Commissioner of Patents has the power to rectify the register to remove invalid PTEs. Competitors can also initiate court proceedings to revoke specific PTEs, or can launch products at commercial risk without waiting for rectification. Until the High Court rules on Otsuka’s appeal, the legal position remains unsettled, but affected PTEs are materially vulnerable to challenge.<\/p>\n\n\n\n

Q3: How does Australia’s pharmaceutical patent notification system compare to the US Orange Book?<\/strong><\/p>\n\n\n\n

The comparison is stark. The US Orange Book is a publicly maintained database that lists all patents a drug company claims cover an approved product, tied directly to the FDA approval process. Generic applicants must certify their position on each listed patent, and challenging a patent triggers a formal litigation process with an automatic 30-month approval stay. Australia has no equivalent public patent-drug linkage database. The TGA does not require patent information as part of drug registration. IP Australia’s AusPat database lists patents but does not link them to ARTG registrations. The Section 26B certificate mechanism under the Therapeutic Goods Act provides a partial notification function, but with a significant loophole allowing generic manufacturers to self-certify non-infringement without notifying patentees. This gap was the subject of failed reform negotiations from 2019 to 2023 and remains a point of tension in US-Australia trade discussions.<\/p>\n\n\n\n

Q4: For a new biologic drug registered in Australia in 2025, what is the realistic total protection period?<\/strong><\/p>\n\n\n\n

A new biologic registered in Australia in 2025 would typically have been patented in the early-to-mid 2010s, given the long development timelines for biologics. A compound patent filed in 2012 and registered on the ARTG in 2025 would have a standard 20-year term expiring in 2032. If the gap between filing and registration (2012 to 2025, i.e., 13 years) exceeds 10 years, the PTE calculation gives the maximum five-year extension, and the patent would expire in 2037. Data exclusivity runs five years from 2025 registration to 2030. The binding constraint is the PTE-extended patent running to 2037. Biosimilar competitors would need to clear that patent before launching commercially. Additional formulation or process patents may extend practical protection in specific areas, though formulation PTEs are now subject to the Otsuka limitation. The realistic period during which the originator faces no significant biosimilar competition is roughly 10-15 years from first Australian registration, depending on the biosimilar development timeline and litigation outcomes.<\/p>\n\n\n\n

Q5: How do analysts practically track when a drug’s Australian patent actually expires, given the complexity of multiple overlapping patents?<\/strong><\/p>\n\n\n\n

Accurately tracking Australian pharmaceutical patent expiry requires reconciling multiple data sources that do not integrate automatically. AusPat at IP Australia provides patent filing and status data. The ARTG at the TGA provides product registration records. Neither directly references the other. Litigation records from the Federal Court must be cross-referenced to identify active infringement proceedings or patent validity challenges. PTE application records must be checked for each patent, and under the post-Otsuka regime, each PTE must then be assessed for whether it covers a compound or formulation to evaluate its current vulnerability. Platforms like DrugPatentWatch aggregate this data across jurisdictions, linking patent filing records to regulatory approval dates and tracking PTE applications and outcomes, to produce integrated exclusivity timelines that would otherwise require teams of specialist analysts to construct manually [18]. For individual products with complex multi-patent portfolios and active litigation, specialist pharmaceutical patent counsel familiar with both Australian and international IP systems remains an essential complement to any data platform.<\/p>\n\n\n\n

\n\n\n\n

Citations<\/strong><\/h2>\n\n\n\n

[1] Clayton Utz. (2025, December). Full Federal Court abolishes patent term extensions for pharmaceutical formulations<\/em>. https:\/\/www.claytonutz.com\/insights\/2025\/december\/full-federal-court-abolishes-patent-term-extensions-for-pharmaceutical-formulations<\/p>\n\n\n\n

[2] Wrays IP. (2023, July 21). Pharmaceutical Patent Term Extensions in Australia<\/em>. https:\/\/wrays.com.au\/insights\/industry-insights\/pharmaceutical-patent-term-extensions-in-australia\/<\/p>\n\n\n\n

[3] Information Justice. (n.d.). The High Price of Drug Patents: Australia, Patent Law, Pharmaceutical Drugs and the Trans-Pacific Partnership<\/em>. https:\/\/infojustice.org\/archives\/35566<\/p>\n\n\n\n

[4] IP Australia. (2020, December 16). 3.12 Extension of Term of Standard Patents Relating to Pharmaceutical Substances<\/em>. IPA Manuals. https:\/\/manuals.ipaustralia.gov.au\/patent\/3.12-extension-of-term-of-standard-patents-relating-to-pharmaceutical-substances<\/p>\n\n\n\n

[5] Spruson & Ferguson. (2019, April 24). Extension of Term for Pharmaceutical Patents in Australia \u2014 Overview and Recent Developments<\/em>. https:\/\/www.spruson.com\/life-science-and-biotechnology\/extension-term-pharmaceutical-patents-australia-overview-recent-developments\/<\/p>\n\n\n\n

[6] James & Wells. (2025, December 4). The Full Federal Backflip: Patent Term Extension Rejected on Pharmaceutical Formulation<\/em>. https:\/\/www.jamesandwells.com\/au\/the-full-federal-backflip-patent-term-extension-rejected-on-pharmaceutical-formulation\/<\/p>\n\n\n\n

[7] Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009\u20132018. JAMA, 323<\/em>(9), 844\u2013853. https:\/\/doi.org\/10.1001\/jama.2020.1166<\/p>\n\n\n\n

[8] Clayton Utz. (2021, July). Patent term extensions in Australia: when first isn’t really first<\/em>. https:\/\/www.claytonutz.com\/insights\/2021\/july\/patent-term-extensions-in-australia-when-first-isnt-really-first<\/p>\n\n\n\n

[9] Kluwer Patent Blog. (2022, March 30). Pharmaceutical patent term extensions now back to the ‘earliest first’ approach, the Full Federal Court confirms<\/em>. https:\/\/legalblogs.wolterskluwer.com\/patent-blog\/pharmaceutical-patent-term-extensions-now-back-to-the-earliest-first-approach-the-full-federal-court-confirms\/<\/p>\n\n\n\n

[10] Herbert Smith Freehills Kramer LLP, Gay, R., & Gilchrist, S. (2021). Pharmaceutical patent term extensions: federal court hears challenge to ‘absurd’ Australian patent office ruling<\/em>. Lexology. https:\/\/www.lexology.com\/library\/detail.aspx?g=a18bf514-0718-47f1-a607-d9075798c58f<\/p>\n\n\n\n

[11] Gestalt Law. (n.d.). Pharmaceutical Patent Term Extensions in Australia: Understanding the Legal Regime<\/em>. https:\/\/www.gestalt.law\/insights\/pharmaceutical-patent-term-extensions-in-australia-understanding-the-legal-regime<\/p>\n\n\n\n

[12] Merck Sharp & Dohme Corp. v Sandoz Pty Ltd<\/em> [2022] FCAFC 40. Full Federal Court of Australia.<\/p>\n\n\n\n

[13] Spruson & Ferguson. (2021, June 16). The Australian Federal Court says ‘Oh No’ to the Patent Office’s interpretation of the first regulatory approval for pharmaceutical patent term extensions<\/em>. https:\/\/www.spruson.com\/the-australian-federal-court-says-oh-no-to-the-patent-offices-interpretation-of-the-first-regulatory-approval-for-pharmaceutical-patent-term-extensions\/<\/p>\n\n\n\n

[14] Lexology. (2021, June 20). Patent term extensions in Australia: a significant victory for pharmaceutical patentees<\/em>. https:\/\/www.lexology.com\/library\/detail.aspx?g=9df170e6-67b7-4341-87f6-255062915cd6<\/p>\n\n\n\n

[15] Griffith Hack. (2025, April 11). Unlocking patent lifespan: An Australian perspective on pharmaceutical patent term extensions<\/em>. https:\/\/www.griffithhack.com\/insights\/publications\/unlocking-patent-lifespan-an-australian-perspective-on-pharmaceutical-patent-term-extensions\/<\/p>\n\n\n\n

[16] Bird & Bird. (2017, December 13). Patent Term Extensions<\/em>. https:\/\/www.twobirds.com\/en\/insights\/2017\/australia\/patent-term-extensions<\/p>\n\n\n\n

[17] DrugPatentWatch. (n.d.). Australia: These 15 Drugs Face Patent Expirations and Generic Entry From 2025\u20132026<\/em>. https:\/\/www.drugpatentwatch.com\/p\/expiring-drug-patents-generic-entry\/Australia<\/p>\n\n\n\n

[18] DrugPatentWatch. (2026, March 8). Track Global Drug Patent Expiry by Geography \u2014 Without Hiring a Team of Analysts<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/track-global-drug-patent-expiry-by-geography-without-hiring-a-team-of-analysts\/<\/p>\n\n\n\n

[19] DrugPatentWatch. (n.d.). Australia: These 37 Drugs Face Patent Expirations and Generic Entry From 2026\u20132027<\/em>. https:\/\/www.drugpatentwatch.com\/p\/generic-entry-opportunity-date\/Australia<\/p>\n\n\n\n

[20] DrugPatentWatch. (2026, January 22). The Patent Cliff and Beyond: A Definitive Guide to Generic and Biosimilar Market Entry<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/generic-drug-entry-timeline-predicting-market-dynamics-after-patent-loss\/<\/p>\n\n\n\n

[21] DrugPatentWatch. (2026, March 10). The Patent Cliff Playbook: Pharmaceutical IP Valuation, Generic Entry Timing, and Biosimilar Strategy<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/patent-expirations-seizing-opportunities-in-the-generic-drug-market\/<\/p>\n\n\n\n

[22] Henriksen, B. (2024). Data exclusivity and patent monopoly extension: A view from Australia. The Journal of World Intellectual Property<\/em>. https:\/\/doi.org\/10.1111\/jwip.12302<\/p>\n\n\n\n

[23] National Library of Medicine \/ PMC. (2018, October 24). Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6201583\/<\/p>\n\n\n\n

[24] Medicines Australia. (2023, March). White Paper on the Patent Notification Scheme<\/em>. https:\/\/www.medicinesaustralia.com.au\/wp-content\/uploads\/sites\/65\/2023\/09\/Public-White-Paper-on-Patent-Notification_MA.pdf<\/p>\n\n\n\n

[25] Griffith Hack. (2025, February 9). What’s going on with Australia’s proposed patent notification scheme for generic and biosimilar medicines?<\/em> https:\/\/www.griffithhack.com\/insights\/publications\/whats-going-on-with-australias-proposed-patent-notification-scheme-for-generic-and-biosimilar-medicines\/<\/p>\n\n\n\n

[26] Springer Nature. (2021). Patent Linkages and Its Impact on Access to Medicines: Challenges and Opportunities for Developing Countries<\/em>. https:\/\/link.springer.com\/chapter\/10.1007\/978-3-030-83114-1_12<\/p>\n\n\n\n

[27] Allens. (2019, April 23). Faster TGA disclosure \u2014 what it means for pharmaceutical patent litigation<\/em>. https:\/\/www.allens.com.au\/insights-news\/insights\/2019\/04\/faster-tga-disclosure—what-it-means-for-pharmaceutical\/<\/p>\n\n\n\n

[28] The Conversation. (2025, May 22). Trump has Australia’s generic medicines in his sights. And no-one’s talking about it<\/em>. https:\/\/theconversation.com\/trump-has-australias-generic-medicines-in-his-sights-and-no-ones-talking-about-it-253836<\/p>\n\n\n\n

[29] Pearce IP. (2025, December 4). Breaking News \u2014 Formulation Patents No Longer Extensible in Australia as Pharmaceutical Patentees Prepare for PTE Shake Down<\/em>. https:\/\/www.pearceip.law\/2025\/12\/04\/breaking-news-formulation-patents-no-longer-extensible-in-australia-as-pharmaceutical-patentees-prepare-for-pte-shake-down\/<\/p>\n\n\n\n

[30] Pearce IP. (2026, March 12). BREAKING NEWS: Australian High Court Grants Leave to Appeal to Otsuka in PTE Dispute<\/em>. https:\/\/www.pearceip.law\/2026\/03\/12\/breaking-news-australian-high-court-grants-leave-to-appeal-to-otsuka-in-pte-dispute\/<\/p>\n\n\n\n

[31] Pearce IP. (2025, December 9). The End of an Era for Pharma PTEs in AU \u2014 Full Court Excludes Formulation Patent Term Extensions in Aripiprazole (ABILIFY) Appeal<\/em>. https:\/\/www.pearceip.law\/2025\/12\/09\/the-end-of-an-era-for-pharma-ptes-in-au-full-court-excludes-formulation-patent-term-extensions-in-aripiprazole-abilify-appeal\/<\/p>\n\n\n\n

[32] Dentons. (2026, February 28). Patent Term Extension in Australia: implications of Otsuka v Sun Pharma and changes in IP Australia practice<\/em>. https:\/\/www.dentons.com\/en\/insights\/articles\/2026\/february\/28\/patent-term-extension-in-australia-implications-of-otsuka-v-sun-pharma<\/p>\n\n\n\n

[33] Bird & Bird. (2026, February 22). Full Federal Court Restricts Patent Term Extensions to Active Pharmaceutical Ingredients<\/em>. https:\/\/www.twobirds.com\/en\/insights\/2026\/australia\/full-federal-court-restricts-patent-term-extensions-to-active-pharmaceutical-ingredients-what-the-ph<\/p>\n\n\n\n

[34] IPKat. (2026, March 2). Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia<\/em>. https:\/\/ipkitten.blogspot.com\/2026\/03\/otsuka-seeks-to-appeal-decision-to-deny.html<\/p>\n\n\n\n

[35] Allens. (2025, December). Applying for a patent term extension in Australia: the formulation for success has changed<\/em>. https:\/\/www.allens.com.au\/insights-news\/insights\/2025\/12\/applying-for-a-patent-term-extension-in-australia-the-formulation-for-success-has-changed\/<\/p>\n\n\n\n

[36] Chambers and Partners. (2026, February 12). Patent Litigation 2026 \u2014 Australia: Trends and Developments<\/em>. https:\/\/practiceguides.chambers.com\/practice-guides\/patent-litigation-2026\/australia\/trends-and-developments<\/p>\n\n\n\n

[37] Pearce IP. (2026, February 27). Hot Topic \u2014 A Seismic Shift in Australian Pharma Patent Strategy as Fault Lines Emerge in PTEs and Preliminary Injunctions<\/em>. https:\/\/www.pearceip.law\/2026\/02\/27\/hot-topic-a-seismic-shift-in-australian-pharma-patent-strategy-as-fault-lines-emerge-in-ptes-and-preliminary-injunctions\/<\/p>\n\n\n\n

[38] Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd<\/em> [2025] FCAFC 161. Full Federal Court of Australia.<\/p>\n\n\n\n

[39] Cipla Australia Pty Ltd v Novo Nordisk A\/S<\/em> [2024] FCA 1414. Federal Court of Australia.<\/p>\n\n\n\n

[40] Merck Sharp & Dohme Corp. v Sandoz Pty Ltd<\/em> [2022] FCAFC 40. Full Federal Court of Australia.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Number Everyone Gets Wrong Twenty years. Ask any pharma executive or patent attorney how long a drug patent lasts […]<\/p>\n","protected":false},"author":1,"featured_media":38551,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38544"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38544\/revisions"}],"predecessor-version":[{"id":38552,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38544\/revisions\/38552"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38551"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}